Disclosure The author has no interests which might be perceived as posing a conflict or a bias.
Tenofovir: what have over 1 million years of patient experience taught us?
Article first published online: 10 JUL 2008
© 2008 The Author. Journal compilation © 2008 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 62, Issue 8, pages 1285–1293, August 2008
How to Cite
Pozniak, A. (2008), Tenofovir: what have over 1 million years of patient experience taught us?. International Journal of Clinical Practice, 62: 1285–1293. doi: 10.1111/j.1742-1241.2008.01817.x
- Issue published online: 10 JUL 2008
- Article first published online: 10 JUL 2008
- Paper received January 2008, accepted May 2008
Several groundbreaking trials and over 1 million years of patient experience have established tenofovir as an important component of HIV treatment. Tenofovir has demonstrated potent antiviral efficacy, with a low risk of developing resistance when used as part of an effective combination regimen. It is generally well tolerated, with a low risk of lipoatrophy and a favourable effect on lipid profile compared with older nucleoside analogue agents such as stavudine or zidovudine. Clinical data suggest that switching from thymidine analogues to a tenofovir-containing regimen can benefit patients with lipid abnormalities or lipoatrophy. This article reviews the development of tenofovir, including pivotal studies that have influenced HIV clinical practice.